Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial

Author:

Böhm Michael12,Butler Javed34,Mahfoud Felix1,Filippatos Gerasimos5,Ferreira João Pedro67,Pocock Stuart J.8,Slawik Jonathan1,Brueckmann Martina910,Linetzky Bruno11,Schüler Elke12,Wanner Christoph13,Zannad Faiez67,Packer Milton1415,Anker Stefan D.16,

Affiliation:

1. Klinik für Innere Medizin III Universitätsklinikum des Saarlandes, Saarland University Saarland Germany

2. Cape Heart Institute Cape Town South Africa

3. Department of Medicine University of Mississippi School of Medicine Jackson MS USA

4. Baylor Scott and White Research Institute Dallas Texas USA

5. National and Kapodistrian University of Athens School of Medicine Athens University Hospital Attikon Athens Greece

6. Centre d'Investigation Clinique‐ Plurithématique Inserm CIC‐P 1433 Université de Lorraine Nancy France

7. France Inserm U1116, CHRU Nancy Brabois F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Nancy France

8. Department of Medical Statistics London School of Hygiene & Tropical Medicine London UK

9. Boehringer Ingelheim International Ingelheim Germany

10. First Department of Medicine, Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany

11. Eli Lilly Interamerica Inc, Suc Argentina Buenos Aires Argentina

12. mainanalytics GmbH Sulzbach/Taunus Germany

13. Medizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie Universitätsklinikum Würzburg Würzburg Germany

14. Baylor University Medical Center Dallas TX USA

15. Imperial College London UK

16. Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin Charité Universitätsmedizin Berlin Berlin Germany

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3